Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Default user image.

Carsten Peterson

Expert

Default user image.

Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases.

Författare

  • Anders Carlsson
  • Christer Wingren
  • Malin Nordström
  • Carsten Rose
  • Mårten Fernö
  • Håkan Olsson
  • Helena Jernstöm
  • Sara Ek
  • Elin Gustavsson
  • Christian Ingvar
  • Mattias Ohlsson
  • Carsten Peterson
  • Carl Borrebaeck
Visa allt

Summary, in English

The risk of distant recurrence in breast cancer patients is difficult to assess with current clinical and histopathological parameters, and no validated serum biomarkers currently exist. Using a recently developed recombinant antibody microarray platform containing 135 antibodies against 65 mainly immunoregulatory proteins, we screened 240 sera from 64 patients with primary breast cancer. This unique longitudinal sample material was collected from each patient between 0 and 36 mo after the primary operation. The velocity for each serum protein was determined by comparing the samples collected at the primary operation and then 3-6 mo later. A 21-protein signature was identified, using leave-one-out cross-validation together with a backward elimination strategy in a training cohort. This signature was tested and evaluated subsequently in an independent test cohort (prevalidation). The risk of developing distant recurrence after primary operation could be assessed for each patient, using her molecular portraits. The results from this prevalidation study showed that patients could be classified into high- versus low-risk groups for developing metastatic breast cancer with a receiver operating characteristic area under the curve of 0.85. This risk assessment was not dependent on the type of adjuvant therapy received by the patients. Even more importantly, we demonstrated that this protein signature provided an added value compared with conventional clinical parameters. Consequently, we present here a candidate serum biomarker signature able to classify patients with primary breast cancer according to their risk of developing distant recurrence, with an accuracy outperforming current procedures.

Avdelning/ar

  • Institutionen för immunteknologi
  • Bröstcancer-genetik
  • Kirurgi, Lund
  • Computational Biology and Biological Physics - Has been reorganised
  • EpiHealth: Epidemiology for Health
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation

Publiceringsår

2011

Språk

Engelska

Sidor

14252-14257

Publikation/Tidskrift/Serie

Proceedings of the National Academy of Sciences

Volym

108

Issue

34

Dokumenttyp

Artikel i tidskrift

Förlag

National Academy of Sciences

Ämne

  • Cancer and Oncology
  • Surgery

Aktiv

Published

ISBN/ISSN/Övrigt

  • ISSN: 1091-6490